

15 December 2006

The Manager Companies  
Australian Stock Exchange Limited  
20 Bridge Street  
SYDNEY NSW 2000

(1 page by email)

Dear Madam,

**BIT225 PRESENTATION AT INTERNATIONAL HIV MEETING, CANCUN, MEXICO**

The Directors are pleased to advise that Biotron Limited ('Biotron') has presented preclinical efficacy data on its anti-HIV drug BIT225 at HIV DART 2006 in Cancun, Mexico. HIV DART 2006 focused on 'Frontiers in Drug Development for Antiretroviral Therapies' and assembled clinicians, researchers, scientists and pharmaceutical company representatives from around the world.

Biotron presented preclinical data showing the antiviral effect of BIT225 in macrophage cells. These cells are one of the major reservoirs of HIV infection in humans, and current HIV treatments are not effective against HIV in these cells. In HIV-infected patients HIV hides in the reservoir cells, where it replicates and is released into the blood, where it infects CD4 T cells, setting up a continual cycle of infection and re-infection in the body. Biotron presented data demonstrating that BIT225 is able to prevent spread of virus between these reservoir cells and also stops transmission of HIV to CD4 T cells.

Biotron's presentation on BIT225 received an award at the meeting, demonstrating the high level of interest in its antiviral program. The award is also an acknowledgement of the robustness of the science underlying the Company's programs.

BIT225 represents a novel, first in class approach to the treatment of HIV. BIT225 is specifically active in HIV reservoir cells and represents an opportunity to attack HIV at its source. As previously advised, the Company is currently completing formal preclinical safety studies and preparing ethics and regulatory submissions for approval to commence human clinical trials early in 2007.

For further information, please contact Dr Michelle Miller, CEO, on (61-2) 61258001.

Yours faithfully



Peter J. Nightingale  
Company Secretary

pjn3751